Trial Profile
A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms MEDI4736; POSTCARD
- 17 Apr 2023 Planned End Date changed from 21 Nov 2024 to 27 Dec 2024.
- 17 Apr 2023 Planned primary completion date changed from 21 Nov 2023 to 27 Dec 2023.
- 17 Apr 2023 Status changed from recruiting to active, no longer recruiting.